瑞格列奈治疗2型糖尿病的有效性和安全性

Efficacy and safety of Repaglinide in treatment of patients with Type 2 Diabetes Mellitus

目的 评价瑞格列奈治疗2型糖尿病的有效性和安全性。方法选择2型糖尿病患者126例,随机分入瑞格列奈组和格列苯脲组,治疗观察时间12周。结果治疗4,8,12周后两组患者的空腹血糖、餐后2h血糖、HbA1c水平均较治疗前有显著下降(P<0.05),两组之间无差异。瑞格列奈组不良反应发生率及严重程度均低于格列苯脲组,低血糖的发生率显著地低于格列苯脲组(3.17％对14.29％,P<0.01)。结论瑞格列奈治疗2型糖尿病安全有效。

Objective To evaluate the efficacy and safety of an antidiabetic agent repaglinide in the treatment of type 2 diabetes. Method 126 cases of type 2 diabetes patients were randomly assigned to repaglinide group or glibenclamide group. The whole observation lasted 12 weeks. Result Similar decreases in fasting blood glucose, 2h postprandial blood glucose and HbA1c were showed in both repaglinide and glibenclamide groups. There was a lower incidence of hypoglycemia by repaglinide thanglibenclamide (3. 17% vs14. 29% , P<0. 01) . Conclusion Repaglinide is effective and safe in the treatment of new diagnostic type 2 diabetes.